MannKind Corporation (MNKD): A Bull Case Theory [Yahoo! Finance]
MannKind Corporation (MNKD)
Last mannkind corporation earnings: 2/25 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.mannkindcorp.com/press-releases
Company Research
Source: Yahoo! Finance
MannKind Corporation's share was trading at $3.5000 as of February 25th. MNKD's trailing and forward P/E were 49.91 and 34.36, respectively according to Yahoo Finance. Top 12 Anesthesiology Residency Programs in 2018 Cherries/Shutterstock.com MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. MNKD is emerging as a compelling growth story, driven by its lead product, Afrezza, an inhalable insulin for both Type 1 and Type 2 diabetes. While adoption has been slower than some shareholders hoped, the product is steadily gaining traction as a convenient alternative to traditional insulin administration. The company has filed with the FDA to expand Afrezza's label to include pediatric patients, and approval—expected potentially in the second quarter of 2026—could meaningfully broaden its addressable market. This expansion positions Afrezza to capture new patients and potentially accelerate revenue
Show less
Read more
Impact Snapshot
Event Time:
MNKD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNKD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNKD alerts
High impacting MannKind Corporation news events
Weekly update
A roundup of the hottest topics
MNKD
News
- MannKind Corp (MNKD) Q4 2025 Earnings Call Highlights: Record Revenue and Strategic ... [Yahoo! Finance]Yahoo! Finance
- MannKind Announces Settlement of Convertible Senior Notes [Yahoo! Finance]Yahoo! Finance
- MannKind Announces Settlement of Convertible Senior NotesGlobeNewswire
- MannKind (MNKD) had its price target lowered by Wedbush from $10.00 to $8.00. They now have an "outperform" rating on the stock.MarketBeat
- MannKind to Participate in Upcoming Investor Conferences [Yahoo! Finance]Yahoo! Finance
MNKD
Earnings
- 2/26/26 - Beat
MNKD
Sec Filings
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- 3/3/26 - Form 4
- MNKD's page on the SEC website